2nd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$4,820,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 1314: Trade Act of 2015 - Provisions related to Trade Promotion Authority H.R. 2146: Defending Public Safety Employees' Retirement Act (Title I is the Bipartisan Congressional Trade Priorities and Accountability Act of 2015) - Provisions related to trade authority S. 995: Bipartisan Congressional Trade Priorities and Accountability Act of 2015 - Provisions related to trade authority Biopharmaceutical innovation policy issues China intellectual property and market access issues India innovation, intellectual property, and market access issues International market access and intellectual property issues Issues related to PhRMAs Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues including mutual recognition of inspections Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues U.S.-Korea Free Trade Agreement: Implementation issues related to intellectual property and market access Canada intellectual property and market access issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHARLES M. CLAPTON —
CHESTER (CHIP) DAVIS —
JEFFREY FRANCER —
DAVID KORN —
COURTNEY LEE-ASHLEY New Assistant to the Chief of Staff, US Senator Ben Nelson
COLLEEN MALONEY —
CARA MOON —
JENNIFER ROMANS —
NICK SHIPLEY —
JAMES M SPEARS —
SARAH AMY SPURGEON —
MATTHEW L SULKALA —
JAY TAYLOR —

Contacted: Patent & Trademark Office (PTO); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Congressional Budget Office (CBO); Office of Management & Budget (OMB)

Bills named: H.R. 1314 (114th), S. 995 (114th), H.R. 2146 (114th)

Copyright/Patent/Trademark CPT

S. 131: Fair And Immediate Release of Generic Drugs Act (FAIR Generics Act) - Provisions related to patent settlements and patent enforcement S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration S. 632: STRONG Patents Act of 2015 - Provisions related to post-grant proceedings, bad faith demand letters, and PTO diversion S. 926: Grace Period Restoration Act of 2015 - Provisions related to grace period and patent law S. 1137: PATENT Act - Provisions related to patent litigation reform and post-grant proceedings at the Patent and Trademark Office (PTO) S. 1421: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 - Provisions related to exclusivity H.R. 9: Innovation Act - Provisions related to patent litigation and post-grant proceedings at the PTO H.R. 406: Combination Drug Development Incentive Act of 2015 - Provisions related to exclusivity and clinical investigations essential to approval H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration H.R. 971: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 - Provisions related to extension of marketing exclusivity H.R. 1353: PATIENT Act of 2015 - Provisions related to extension of marketing exclusivity H.R. 1791: Grace Period Restoration Act of 2015 - Provisions related to grace period and patent law H.R. 1832: Innovation Protection Act - Provisions related to patent office fees H.R. 2045: Targeting Rogue and Opaque Letters Act of 2015 - Provisions related to demand letters Issues related to abuse deterrent exclusivity incentives Patent litigation reform issues and issues related to post-grant proceedings at the PTO Biopharmaceutical innovation and patent policy issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHARLES M. CLAPTON —
CHESTER (CHIP) DAVIS —
PETER FOTOS —
SASCHA HAVERFIELD-GROSS —
DAVID KORN —
COURTNEY LEE-ASHLEY New Assistant to the Chief of Staff, US Senator Ben Nelson
COLLEEN MALONEY —
CARA MOON —
ANNE PRITCHETT —
LORI REILLY —
JENNIFER ROMANS —
NICK SHIPLEY —
PAMELA SMITH —
JAMES M SPEARS —
SARAH AMY SPURGEON —
MATTHEW L SULKALA —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 926 (114th), H.R. 639 (114th), S. 632 (114th), H.R. 1353 (114th), S. 131 (114th), H.R. 2045 (114th), H.R. 971 (114th), S. 1421 (114th), H.R. 406 (114th), H.R. 9 (114th), S. 481 (114th), H.R. 1832 (114th), S. 1137 (114th), H.R. 1791 (114th)

Budget/Appropriations BUD

H.R. 1078: Food and Drug Administration Safety Over Sequestration Act of 2015 - Provisions related to exemption of certain user fees from sequestration H.R. 1735: National Defense Authorization Act for Fiscal Year 2016 - Provisions related to Tricare prescription reimbursement in this bill, which authorizes FY2016 appropriations and sets forth policies for Department of Defense (DOD) programs and activities FY 2016 Labor, Health and Human Services, and Education Appropriations Bill - Provisions related to drug reimbursement, Part D, and biopharmaceutical research FY 2016 Agriculture Appropriations Bill - Provisions related to compounding and e-labeling The Presidents FY 2016 Budget - Provisions related to prescription drug reimbursement and data exclusivity FY 2016 Budget Resolution - Provisions related to biopharmaceutical policy issues Budget Control Act - Provisions related to sequestration

Contacted: Congressional Budget Office (CBO); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Office of Science & Technology Policy (OSTP); U.S. Trade Representative (USTR); Food & Drug Administration (FDA)

Bills named: H.R. 1078 (114th), H.R. 1735 (114th)

Health Issues HCR

S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 337: FOIA Improvement Act of 2015 - Provisions related to the Freedom of Information Act (FOIA) S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the Controlled Substances Act (CSA) S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) S. 1406: Saving Access to Compounded Medications for Special Needs Patients Act - Provisions related to the Drug Quality and Security Act regarding compounding H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the CSA H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to DEA scheduling H.R. 786: Vaccine Access, Certainty, and Innovation Act of 2015 - Provisions related to vaccine development H.R. 880: American Research and Competitiveness Act of 2015 - Provisions related to the research and development (R&D) tax credit H.R. 909: Andrea Sloan Compassionate Use Reform and Enhancement Act - Provisions related to expanded access H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Government Accountability Office (GAO) study on generic versions of complex drug products H.R. 2433: To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review - Provisions regarding the enhancement of combination products review H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2629: Antibiotic Development to Advance Patient Treatment Act - Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of certain covered products to generic manufacturers for bioequivalence testing Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Drug Supply Chain Security Act implementation issues Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program issues General FDA advocacy Biopharmaceutical and medical innovation policy issues Drug development ecosystem issues Drug cost and pricing policy issues NIH Funding issues Precision Medicine Initiative Biomarker proposed legislation - Draft legislation related to developing a new approval pathway for biomarkers Rogue Internet Pharmacy issues Prescription drug abuse issues

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP); SENATE; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR)

Bills named: H.R. 1455 (114th), S. 483 (114th), H.R. 471 (114th), H.R. 909 (114th), S. 1128 (114th), H.R. 1576 (114th), S. 337 (114th), H.R. 2479 (114th), S. 481 (114th), H.R. 2841 (114th), H.R. 2433 (114th), H.R. 639 (114th), H.R. 880 (114th), H.R. 2629 (114th), H.R. 6 (114th), S. 320 (114th), S. 1406 (114th), H.R. 786 (114th), S. 289 (114th), S. 122 (114th), H.R. 1537 (114th)

Medicare/Medicaid MMM

S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions relating to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 2570: Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 - Provisions related to changes to the Medicare Advantage Program H.R. 2581: Preservation of Access for Seniors in Medicare Advantage Act of 2015 - Provisions related to changes to the Medicare Advantage Program H.R.__: To amend title XVIII of the Social Security Act to establish a program to improve care for the highest cost Medicare fee-for-service beneficiaries, and for other purposes - Provisions relating to changes to the Part D benefit S.___: Stopping Medicare Abuse and Protecting Seniors Act of 2015 - Provisions related to Part D Lock-in program Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Cancer Care Payment Reform Act (discussion draft) - Provisions related to oncology medical home demonstration Fighting Medicare Fraud Act (discussion draft) - Provisions related to exclusion from federal healthcare programs Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) issues Medicare exclusion issues Medicare Part D rebates issues Drug cost and pricing policy issues

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; Congressional Budget Office (CBO); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2298 (114th), S. 648 (114th), H.R. 1725 (114th), H.R. 1190 (114th), S. 1083 (114th), S. 31 (114th), H.R. 2005 (114th), S. 1253 (114th), S. 1396 (114th), S. 141 (114th), S. 480 (114th), H.R. 2581 (114th), H.R. 2570 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.